Pediatrics Doctors in Howell, NJ Accepting Medicare

8 Pediatrics doctors found. Showing 1 - 8

Mr. Vicente Nevardo Lozada Mision, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 403 Candlewood Commons, Howell, NJ 07731 Phone: 732-370-1900    Fax: 732-901-0916

Luis T Manlapid, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 700 Candlewood Commons, Howell, NJ 07731 Phone: 732-367-3130    Fax: 732-901-2539

Dr. Sangita Nagpal, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 300 Candlewood Commons, Howell, NJ 07731 Phone: 732-370-9600    Fax: 732-370-9656

Dr. Rose Mylaine Q Maddatu, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 70 Ramtown Greenville Rd, Howell, NJ 07731 Phone: 732-785-0300    Fax: 732-785-9420

Dr. Elizabeth Mariano-lau, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 5140 Route 9 South, Howell, NJ 07731 Phone: 732-364-4141    Fax: 732-364-0787

Dr. Alicia G Deperio, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4679 Route 9 N, Suite #8, Howell, NJ 07731 Phone: 732-905-9505    Fax: 732-905-2448

Dr. Chi Yeung Lau, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 5140 Route 9 South, Howell, NJ 07731 Phone: 732-364-4141    Fax: 732-364-0787

Dr. Elenito Maddatu, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 70 Ramtown Greenville Rd, Howell, NJ 07731 Phone: 732-785-0300    Fax: 732-785-9420

News Archive

Researchers propose a new group testing method for COVID-19

Researchers Mario Guarracino from the HSE Laboratory of Algorithms and Technologies for Networks Analysis in Nizhny Novgorod and Julius Žilinskas and Algirdas Lančinskas from Vilnius University, have proposed a new method of testing for COVID-19.

Biotechnological approach to fight H1N1 influenza

ETBOND TECHNOLOGY defines Biotechnology approach to fight H1N1 Influenza A (Swine Flu)

Seattle Genetics, Genentech expand antibody-drug conjugate collaboration

Seattle Genetics, Inc. announced today that it has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech, Inc., a member of the Roche Group. Under the expanded agreement, Genentech will pay an upfront fee of $12 million for rights to utilize Seattle Genetics' ADC technology with additional antigens to be named by Genentech.

FDA accepts ARIAD's ponatinib NDA for filing

ARIAD Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for accelerated review of ARIAD's investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

Read more Medical News

› Verified 1 days ago